Loading stock data…
DGX
$204.53+7.32 (+3.71%)
After Hours$188.57-15.96 (-7.80%)· Last close Jun 9
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quest Diagnostics Incorporated in the Healthcare sector is trading at $204.53 with a market capitalization of $21.5B. Wall Street consensus targets $223.44 (16 analysts), implying a +9.2% move over the next 12 months. The stock is currently near its 52-week high of $213.50, remaining 9.0% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +9.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$204.53
Potential Downside
7.4%
Whystock Fair Value$189.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Buy
Mean target$223.44+9.2%
Range$184.00 – $245.00
Fundamentals
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$21.50B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.44
Beta
Defensive asset. Lower volatility than the S&P 500.
0.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.59%
ROE
Average efficiency. Growth may require heavy reinvestment.
13.90%
Volume
Today's trading volume
572,007
Recent News
4 Outpatient Home Health Stocks Benefiting From Industry Trends
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes
Quest Diagnostics is in focus today as the latest update shows no changes to the current price targets set by covering analysts. Even without fresh commentary driving the story, the lack of adjustment itself can be useful context as you think about how the stock fits into your watchlist or portfolio. Read on to see how to monitor future shifts in the analyst narrative so you can stay on top of what changes and what stays the same. Wall Street's queuing for one rocket. While SpaceX counts down...
DaVita HealthCare (DVA) Up 0.6% Since Last Earnings Report: Can It Continue?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health to Expand WV Footprint With 36-Bed Bridgeport Unit
EHC is expanding its rehabilitation network with a new 36-bed hospital in West Virginia.
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.